Phase 1A safety and pharmacokinetics (PK) of ABI-H0731, a novel core protein allosteric modifier (CPAM) for the treatment of chronic HBV infection

Authors
Category Primary study
JournalHepatology
Year 2017
This article has no abstract
Epistemonikos ID: 8e12d781b483cc9587afe912e134e5a9c4f26f34
First added on: Feb 08, 2025